<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03166800</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00015779</org_study_id>
    <nct_id>NCT03166800</nct_id>
  </id_info>
  <brief_title>MitoQ for Fatigue in Multiple Sclerosis</brief_title>
  <acronym>MS</acronym>
  <official_title>MitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MitoQ Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MS patients who receive Oral mitoquinone&#xD;
      (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's&#xD;
      fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if&#xD;
      MitoQ has a significant change in fatigue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MitoQ is a potent antioxidant dietary supplement with potentially significant&#xD;
      immunomodulatory and anti-inflammatory properties. While the cause of MS related fatigue is&#xD;
      uncertain, the investigators believe that mitochondria dysfunction and resultant neuronal&#xD;
      energy depletion may be an important contributor to fatigue in MS.&#xD;
&#xD;
      This clinical trial will evaluate the potential beneficial effects of MitoQ on MS fatigue. It&#xD;
      will also explore the effects of MitoQ on cognitive function, quality of life and mood. If&#xD;
      enrolled in the study, patients will take two capsules of the study drug or placebo at the&#xD;
      same time every day for twelve weeks. There will be 4 study visits where the participant will&#xD;
      undergo medical and nervous system examinations, questionnaires, and blood draws. Because it&#xD;
      is a placebo-controlled trial, participants will have a 33% chance of receiving either&#xD;
      placebo (inactive), 20mg of MitoQ, or 40mg of MitoQ. This will be a blinded randomized study,&#xD;
      meaning neither the participant nor the investigator will know who received the placebo or&#xD;
      study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2018</start_date>
  <completion_date type="Actual">November 5, 2019</completion_date>
  <primary_completion_date type="Actual">November 5, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue measured by Modified Fatigue Impact Scale (MFIS) Score at 12 weeks post study drug initiation</measure>
    <time_frame>Baseline to 12 weeks post drug initiation.</time_frame>
    <description>This primary outcome measure will be the difference from baseline in fatigue scores as measured by Modified Fatigue Impact Scale (MFIS) Score at 12 weeks post study drug initiation.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 subjects will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg oral MitoQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 20mg of MitoQ will be administered to 20 subjects in this trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40mg oral MitoQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 40mg of MitoQ will be administered to 20 subjects in this trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoquinone</intervention_name>
    <description>MitoQ will administered in either 20mg or 40mg capsules. The dose will administered for a 12-weeks treatment.</description>
    <arm_group_label>20mg oral MitoQ</arm_group_label>
    <arm_group_label>40mg oral MitoQ</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>mitoquinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MS (any clinical subtype) as diagnosed by the 2010 McDonald criteria40;&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score of 2 to 8,&#xD;
&#xD;
          -  Complaint of fatigue that has been persistent for at least two months;&#xD;
&#xD;
          -  Modified Fatigue Impact Scale (MFIS) score of 38 or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with systemic glucocorticoids in the prior six weeks;&#xD;
&#xD;
          -  Beck Depression Inventory (BDI) &gt;31 (severe depression);&#xD;
&#xD;
          -  Significant MS exacerbation in prior 30 days;&#xD;
&#xD;
          -  Previous use of MitoQ or CoQ-10 within 30 days of screening appointment;&#xD;
&#xD;
          -  Use of non-research-pharmacy-administered MitoQ or CoQ-10 during the duration of the&#xD;
             study;&#xD;
&#xD;
          -  Other significant health problem (e.g. active coronary heart disease, liver disease,&#xD;
             pulmonary disease, diabetes mellitus) that might increase risk of patient experiencing&#xD;
             adverse events),&#xD;
&#xD;
          -  Pregnancy or intending to become pregnant or breastfeeding;&#xD;
&#xD;
          -  Unable to complete the self-report forms;&#xD;
&#xD;
          -  Unable to give informed consent;&#xD;
&#xD;
          -  Prisoners will be excluded.&#xD;
&#xD;
          -  Any condition which would make the patient, in the opinion of the investigator,&#xD;
             unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijayshree Yadav, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Vijayshree Yadav</investigator_full_name>
    <investigator_title>MD, MCR, FANA</investigator_title>
  </responsible_party>
  <keyword>mitoquinone</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

